FDA Embraces Total-Time Pre-Market Review Goals, With Shared Accountability
This article was originally published in The Gray Sheet
Executive Summary
FDA negotiators have warmed to the idea of total-time performance goals for the next round of medical device user fees, beginning in 2012, as long as FDA and industry share accountability for the time it takes to review new products.
You may also be interested in...
FDA Releases Guidance Documents On PMA, 510(k) Review Times And Goals
The agency outlined how it plans to calculate review times and meet performance goals for PMA and 510(k) submissions in two recent guidance documents.
Device Industry Expects Quicker Path To Market In Exchange For Doubling Of User Fees
The tentative agreement of $595 million in user fees over five years is more than companies had wanted to spend. But industry negotiators insist it is a good deal, tied to performance goals and process improvements they say will ensure greater speed and predictability in reaching the U.S. market.
Regulatory News In Brief
The latest on user fee negotiations and other device regulatory issues.